Monogram Biosciences last week said that preliminary data from a study of its HERmark assay suggests that it may be an improvement over immunohistochemistry- and fluorescence in situ hybridization-based tests in determining which patients with metastatic breast cancer will likely benefit from Herceptin therapy.
The company said it would present the findings in more detail on June 2 at the American Society of Clinical Oncology's annual meeting in Chicago.